Castle Biosciences (CSTL) Short term Debt (2019 - 2026)

Castle Biosciences has disclosed Short term Debt across 6 years of filings, most recently posting $1.7 million for Q1 2026.

• Short term Debt for Q1 2026 came in at $1.7 million, up 50.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (up 50.05% YoY), and the FY2025 annual result was $417000.0, up 50.0% from the prior year.
• Short term Debt came in at $1.7 million for Q1 2026 at Castle Biosciences, up from $417000.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $20.8 million in Q1 2022 to a low of $278000.0 in Q4 2024.
• The 4-year median for Short term Debt is $1.4 million (2025), against an average of $4.4 million.
• Across the five-year window, Short term Debt jumped 50.0% in 2025 and surged 50.05% in 2026, its largest moves.
• Castle Biosciences' Short term Debt stood at $20.8 million in 2022, then slumped by 98.67% to $278000.0 in 2024, then surged by 50.0% to $417000.0 in 2025, then surged by 299.76% to $1.7 million in 2026.
• The last three Short term Debt figures came in at $1.7 million (Q1 2026), $417000.0 (Q4 2025), and $1.9 million (Q2 2025), per Business Quant data.